Online inquiry

IVTScrip™ mRNA-Anti-F3, HuMax-TF(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ8678MR)

This product GTTS-WQ8678MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets F3 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001178096.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2152
UniProt ID P13726
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-F3, HuMax-TF(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ8678MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ5954MR IVTScrip™ mRNA-Anti-IGHE, CL-2C(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA CL-2C
GTTS-WQ5467MR IVTScrip™ mRNA-Anti-tcdB, CDB-1(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA CDB-1
GTTS-WQ9579MR IVTScrip™ mRNA-Anti-EGFR&MET, JNJ-61186372(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA JNJ-61186372
GTTS-WQ3355MR IVTScrip™ mRNA-Anti-MS4A1, AT-004(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA AT-004
GTTS-WQ6912MR IVTScrip™ mRNA-Anti-Alkaline phosphatase substitute, ENB-0040(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ENB-0040
GTTS-WQ2626MR IVTScrip™ mRNA-Anti-ICOSLG, AMG 557(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA AMG 557
GTTS-WQ7139MR IVTScrip™ mRNA-Anti-CTGF, FG-3019(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA FG-3019
GTTS-WQ14693MR IVTScrip™ mRNA-Anti-MS4A1, SCT-400(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA SCT-400
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW